Linked Life Data

15819595

Source:http://linkedlifedata.com/resource/pubmed/id/15819595

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-4-11
pubmed:abstractText
Subcutaneous peginterferon-alpha-2a (40kD) [Pegasys] is an effective and reasonably well tolerated treatment for the management of patients with hepatitis B e antigen (HBeAg)-negative or -positive chronic hepatitis B. It was significantly more effective than lamivudine monotherapy at inducing sustained virological response and ALT normalisation in both HBeAg-negative and -positive patients. Notably, the addition of lamivudine to peginterferon-alpha-2a (40kD) conferred no additional benefit versus peginterferon-alpha-2a (40kD) monotherapy. Moreover, in HBeAg-positive patients significantly more peginterferon-alpha-2a (40kD) recipients experienced HBeAg seroconversion than lamivudine recipients. The position of peginterferon-alpha-2a (40kD) relative to other treatment options remains to be fully determined. In the meantime, this agent appears to be a valuable new option for the management of patients with HBeAg-negative or -positive chronic hepatitis B.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0012-6667
pubmed:author
pubmed:issnType
Print
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
809-25
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Peginterferon-alpha-2a (40kD): a review of its use in the management of patients with chronic hepatitis B.
pubmed:affiliation
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
pubmed:publicationType
Journal Article, Comparative Study, Review